Norway's ArcticZymes Q1 revenue rises

Arcticzymes Technologies ASA

07/05/2026 06:33

Overview

Norway life sciences firm's Q1 revenue rose, driven by broad-based segment growth

Q1 EBITDA turned positive

Molecular Tools segment rebounded sharply; Biomanufacturing extended commercial reach among global CDMOs

Outlook

Company expects revenue momentum and growing commercial reach across both business segments in 2026

Company aims to convert commercial momentum into sustained, profitable growth in 2026

Result Drivers

MOLECULAR TOOLS REBOUND - Segment returned to strong growth, recovering from prior-year quarter affected by order timing, with recurring OEM relationships and growth in research and diagnostics

BIOMANUFACTURING DEMAND - M-SAN HQ product drove growth, winning recurring business with global CDMOs and generating new and repeat orders

Company press release: ID:nWkr92R5xQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
NOK 35 mln
Q1 EBITDA
NOK 1.6 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Arcticzymes Technologies ASA is NOK33.00, about 38.1% above its May 6 closing price of NOK23.90

The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 49 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)